1 Subsequent oxidation provides the
indolequinone.
2 patible with the predicted absorption of 5,6-
indolequinone (
1Q).
3 nd to be opposite to that observed for other
indolequinones acting as substrates.
4 gn of both NQO1-inhibitory and noninhibitory
indolequinone analogues allowed us to test the hypothesi
5 sisting of four monomer units (hydroquinone,
indolequinone,
and its two tautomers), in arrangements t
6 We describe a series of
indolequinones as efficient mechanism-based inhibitors o
7 In this report, we describe a series of
indolequinones,
based on 5-methoxy-1,2-dimethyl-3-[(4-ni
8 sis, and biological validation of a range of
indolequinone-
based bioreductive fluorescent probes.
9 A series of
indolequinones bearing various functional groups has bee
10 To develop HAP-TACs, we have attached an
indolequinone bioreductive group to an essential functio
11 eatic tumor xenograft in nude mice, and lead
indolequinones demonstrated high efficacy and low toxici
12 of the FAD in the active site of NQO2 by an
indolequinone-
derived iminium electrophile to the wider
13 nyltetrazolium (MTT) and clonogenic assays];
indolequinones displayed potent cytotoxicity against all
14 The
indolequinone ES936 {5-methoxy-1,2-dimethyl-3-[(4-nitrop
15 f-concept studies which demonstrate that the
indolequinone group is bioreduced under hypoxic conditio
16 growth inhibitory activity of this series of
indolequinones in human pancreatic cancer.
17 nd may provide a biomarker of effect of lead
indolequinones in this type of cancer.
18 A series of
indolequinones including derivatives of EO9 bearing vari
19 These
indolequinones induced caspase-dependent apoptosis but n
20 Indolequinones inhibited NQO2 activity in K562 cells at
21 iminium electrophile to the wider series of
indolequinone inhibitors.
22 The examination of
indolequinone interactions in complex with NQO1 from com
23 Indolequinones (
IQs) were developed as potential antitum
24 le indole derivatives to their corresponding
indolequinones is described.
25 ed 4-nitrobenzyl (4NB-) resorufin and methyl-
indolequinone (
MeIQ-) resorufin to Arabidopsis thaliana
26 des the key step in a short synthesis of two
indolequinone natural products.
27 specificity exists, but minor changes to the
indolequinone nucleus have a significant effect upon sub
28 A series of 2- and 3-substituted
indolequinone phosphoramidate prodrugs targeted to DT-di
29 Previously a series of 2- and 3-substituted
indolequinone phosphoramidate prodrugs was synthesized,
30 ions demonstrated favorable conformations of
indolequinones positioned directly above and in parallel
31 oles and subsequent oxidation to the desired
indolequinones,
thereby demonstrating a powerful applica
32 The ability of this series of
indolequinones to inhibit recombinant human NQO1 correla
33 The unsaturated nature of C-C bonds in
indolequinone units and the finite size of protomolecule
34 In vivo efficacy of the
indolequinones was also tested in the MIA PaCa-2 pancrea
35 A potential target of these
indolequinones was identified as thioredoxin reductase.
36 Inhibition of recombinant human NQO2 by the
indolequinones was NRH-dependent, with kinetic parameter
37 The mechanism of action of the
indolequinones was shown to involve metabolic reduction,
38 hree cell lines, and two specific classes of
indolequinone were particularly potent agents.
39 Selected
indolequinones were also screened against the NCI-60 cel
40 Indolequinones were found to be potent inhibitors of thi
41 These
indolequinones were irreversible inhibitors and were fou
42 The
indolequinones with 4-nitrophenoxy, 4-pyridinyloxy, and
43 The objective of this study was to identify
indolequinones with improved potency against pancreatic